Abilia acquires LivAssured

Abilia, a subsidiary to MedCap AB (publ) and part of Business Area Assistive Tech, has signed an agreement to acquire LivAssured B.V. in the Netherlands. The transaction is expected to close shortly.

LivAssured's product Nightwatch is a medical device that detects epileptic seizures, and has been developed for more than 10 years with significant commercial progress achieved in Europe in recent years. The company currently has a turnover of approx. 4 MEUR and 15 employees, and an ambitious growth plan. The acquisition complements the offering of Abilia and the Business Area Assistive Tech.

Tove Christiansson, Head of Business Area Assistive Tech and CEO of Abilia comments the acquisition: *"Abilia's mission has always been to empower people through innovative, reliable, and user centric assistive technology"*, says Tove Christiansson, *"With this acquisition, we're deepening that mission, reinforcing our dedication to delivering solutions that truly matter, grounded in evidence, and built through collaboration with key stakeholders. We look forward to welcoming the LivAssured team to Abilia and the Business Area Assistive Tech."*

Jeroen van den Hout, CEO of LivAssured comments the acquisition:
 "We are very proud of what we've achieved with our partners in the epilepsy community," says Jeroen van den Hout *"Joining Abilia allows us to scale our impact and continue delivering trusted, research-based solutions to even more people across Europe and beyond."*

The purchase price consists of an initial cash payment of 9.5 MEUR at closing and a deferred payment of 0.5 MEUR for 100% of the company's shares, and a potential additional payment of up to 4 MEUR contingent upon the gross profit growth in 2026. The acquisition is expected to have a marginally positive impact on MedCap's earnings during the current financial year.

This disclosure contains information that MedCap AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 1-10-2025 15:00 CEST.

For further information, please contact:
Anders Dahlberg, CEO,
Phone +46 704 26 92 62,
e-mail anders.dahlberg@medcap.se

About MedCap:
MedCap builds successful life sciences companies to improve people's lives. MedCap unites the strengths of a larger company with the smaller companies' entrepreneurial power, agility, and business acumen. MedCap is publicly listed on NASDAQ Stockholm OMX, with the symbol MCAP. More information is available on the company web site www.medcap.se.